



Pathophysiological and Therapeutic Perspectives of Type-1 Diabetes

Guest Editor:

Dr. Srinivas Nammi

Discipline of Medical Sciences,
School of Science and NICM-
Health Research Institute,
Western Sydney University,
Sydney, NSW 2751, Australia

Deadline for manuscript
submissions:

closed (30 September 2022)

Message from the Guest Editor

Knowledge on the pathogenesis and natural history of type 1 diabetes has substantially grown in the last few decades. It is an auto-immune condition characterized by the destruction of the pancreatic beta cells, leading to absolute insulin deficiency. The destruction of β -cells is triggered by genetic, environmental and immunologic factors that destroy the endocrine cells of the pancreas, leading to insulin deficiency. Furthermore, inflammation (e.g., interleukin-1 mediated) may play a significant role in islet β -cells loss in type-1 diabetes. Patients with type 1 diabetes may also, coincidentally, have pathophysiological elements of type 2 diabetes.

We invite scientists to contribute both original research articles and reviews that highlight the development of pathophysiological pathways of type-1 diabetes and current therapeutic perspectives. Both basic and translational research papers are welcome.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](https://twitter.com/Biomed_MDPI)